In
this paper, we present an additional, new cage-GABA compound,
called 4-amino-1-(4′-dimethylaminoisopropoxy-5′,7′-dinitro-2′,3′-dihydro-indol-1-yl)-1-oxobutane-γ-aminobutyric
acid (iDMPO-DNI-GABA), and currently, this compound is the only photoreagent,
which can be applied for GABA uncaging without experimental compromises.
By a systematic theoretical design and successful synthesis of several
compounds, the best reagent exhibits a high two-photon efficiency
within the 700–760 nm range with excellent pharmacological
behavior, which proved to be suitable for a complex epileptic study.
Quantum chemical design showed that the optimal length of the cationic
side chain enhances the two-photon absorption by 1 order of magnitude
due to the cooperating internal hydrogen bonding to the extra nitro
group on the core. This feature increased solubility while suppressing
membrane permeability. The efficiency was demonstrated in a systematic,
wide range of in vitro single-cell neurophysiological experiments
by electrophysiological as well as calcium imaging techniques. Scalable
inhibitory ion currents were elicited by iDMPO-DNI-GABA with appropriate
spatial–temporal precision, blocking both spontaneous and evoked
cell activity with excellent efficiency. Additionally, to demonstrate
its applicability in a real neurobiological study, we could smoothly
and selectively modulate neuronal activities during artificial epileptic
rhythms first time in a neural network of GCaMP6f transgenic mouse
brain slices.